Related Experiment Video
Updated: Sep 16, 2025

Author Spotlight: Developing Photo-Stimulation Technology for Toxin Removal in Sleep-Related Brain Diseases
Published on: June 28, 2024
EP300 Regulates CD8br AC (TBNK Panel) to Facilitate Insomnia
1Department of Anesthesiology, Hangzhou Women's Hospital (Hangzhou Maternity and Child Health Care Hospital, Hangzhou First People's Hospital Qianjiang New City Campus, Zhejiang Chinese Medical University), Hangzhou, 310008, China.
This study identifies EP300 as a lactylation-related gene linked to insomnia. EP300 may promote insomnia by affecting immune cells, offering a potential new therapeutic target for sleep disorders.
Area of Science:
- Genetics
- Sleep Medicine
- Immunology
Background:
- Insomnia is a common disorder influenced by multiple factors.
- The role of lactylation-related genes in insomnia pathogenesis is not well understood.
Purpose of the Study:
- To investigate the causal relationship between lactylation-related genes and insomnia.
- To identify potential therapeutic targets for insomnia.
Main Methods:
- Mendelian randomization analysis using cis-expression quantitative trait loci (cis-eQTL) data.
- Validation through summary-data-based MR (SMR) and Gene Expression Omnibus (Geo) data analysis.
- Mediation analysis involving immune cells and EP300 gene expression.
Main Results:
- One lactylation-related gene, EP300, was significantly associated with insomnia.
- EP300 expression differed significantly between insomnia patients and healthy individuals.
- EP300 appears to promote insomnia by regulating CD8br AC (TBNK panel) immune cells.
Conclusions:
- EP300 is implicated in the pathogenesis of insomnia.
- EP300 represents a potential novel therapeutic target for insomnia treatment.
Related Concept Videos
Management of Insomnia
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Insomnia
Multiple factors contribute...
CNS Depressants: Barbiturates and Benzodiazepines
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...

